BLIS Technologies Valuation

Q: What is the Fair Price of BLT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

BLT (NZ$0.02) is trading below our estimate of [[fair value]] (NZ$0.18)

Is BLT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BLT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BLT (NZ$0.02) is trading below our estimate of fair value (NZ$0.18)

Significantly Below Fair Value: BLT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLT?

Key metric: As BLT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BLT. This is calculated by dividing BLT's market cap by their current earnings.
What is BLT's PE Ratio?
PE Ratio	35.6x
Earnings	NZ$646.00k
Market Cap	NZ$23.03m

BLT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.3x
Enterprise Value/EBITDA	29.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does BLT's PE Ratio compare to its peers?

The above table shows the PE ratio for BLT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	17.3x
AFT AFT Pharmaceuticals	17.8x	16.5%	NZ$274.7m
ADVENT Advent Pharma	22.1x	n/a	৳1.5b
538964 Mercury Laboratories	27.4x	n/a	₹1.1b
524652 Ind-Swift	2x	n/a	₹1.1b
BLT BLIS Technologies	35.6x	n/a	NZ$23.0m

Price-To-Earnings vs Peers: BLT is expensive based on its Price-To-Earnings Ratio (35.6x) compared to the peer average (17.3x).

Price to Earnings Ratio vs Industry

How does BLT's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

27 Companies	Price / Earnings	Estimated Growth	Market Cap

27 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: BLT is expensive based on its Price-To-Earnings Ratio (35.6x) compared to the Global Pharmaceuticals industry average (22.8x).

Price to Earnings Ratio vs Fair Ratio

What is BLT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	35.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BLT's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.